Table 2.
Adjusted odds ratios and 95 % confidence intervals from logistic regressions on early stages at BC diagnosis for persistence with mammography screening SEER-Medicare 2005–2009 cases
| Variables | In situ stage
|
Local stage
|
Regional stage
|
||||||
|---|---|---|---|---|---|---|---|---|---|
| AOR | 95 % CI | Sig | AOR | 95 % CI | Sig | AOR | 95 % CI | Sig | |
| Persistence with mammography screening | |||||||||
| Persistent users | 3.28 | (2.75, 3.91) | *** | 2.37 | (2.00, 2.81) | *** | 1.60 | (1.35, 1.91) | *** |
| Non-persistent users | 1 | 1 | 1 | ||||||
| Non-users | 0.07 | (0.06, 0.08) | *** | 0.17 | (0.15, 0.19) | *** | 0.37 | (0.33, 0.42) | *** |
| Age at diagnosis | |||||||||
| 70–74 | 1 | 1 | 1 | ||||||
| 75–79 | 0.97 | (0.84, 1.11) | 1.02 | (0.90, 1.16) | 1.03 | (0.90, 1.17) | |||
| 80+ | 0.79 | (0.69, 0.90) | *** | 1.13 | (1.00, 1.26) | * | 1.00 | (0.88, 1.12) | |
| Race/ethnicity | |||||||||
| White | 1 | 1 | 1 | ||||||
| Black | 1.09 | (0.91, 1.30) | 0.74 | (0.63, 0.86) | *** | 0.85 | (0.72, 0.99) | * | |
| Other | 1.80 | (1.36, 2.38) | *** | 1.37 | (1.06, 1.78) | * | 1.20 | (0.92, 1.56) | |
| Location of residence | |||||||||
| Metro | 1 | 1 | 1 | ||||||
| Non-metro | 1.03 | (0.87, 1.23) | 1.13 | (0.97, 1.32) | 1.06 | (0.91, 1.25) | |||
| Marital status | |||||||||
| Married/Partnered | 1.21 | (1.08, 1.36) | ** | 1.26 | (1.13, 1.40) | *** | 1.21 | (1.08, 1.34) | *** |
| Single/divorced/widowed | 1 | 1 | 1 | ||||||
| Census tract household income | |||||||||
| LE $25,000 | 1 | 1 | 1 | ||||||
| $25,001–50,000 | 1.11 | (0.90, 1.37) | 1.08 | (0.90, 1.28) | 0.94 | (0.79, 1.13) | |||
| $50,001–75,000 | 1.26 | (0.98, 1.61) | 1.15 | (0.93, 1.42) | 1.00 | (0.80, 1.24) | |||
| GT $75,000 | 1.61 | (1.19, 2.18) | ** | 1.57 | (1.21, 2.05) | *** | 1.35 | (1.03, 1.77) | * |
| Census tract education | |||||||||
| 0–13.29 | 1 | 1 | 1 | ||||||
| 13.30–22.83 | 1.11 | (0.95, 1.29) | 1.11 | (0.97, 1.26) | 1.09 | (0.95, 1.25) | |||
| 22.84–8.55 | 1.22 | (1.03, 1.45) | * | 1.17 | (1.01, 1.35) | * | 1.05 | (0.90, 1.22) | |
| ≥38.56 | 1.04 | (0.86, 1.28) | 1.03 | (0.86, 1.23) | 0.90 | (0.75, 1.08) | |||
| Comorbidity | |||||||||
| 0 | 1 | 1 | 1 | ||||||
| 1 | 1.05 | (0.92, 1.19) | 1.02 | (0.91, 1.14) | 1.01 | (0.90, 1.13) | |||
| 2+ | 0.93 | (0.80, 1.07) | 0.94 | (0.83, 1.06) | 0.94 | (0.82, 1.07) | |||
| PCP visits | |||||||||
| 0–10 | 1 | 1 | 1 | ||||||
| 11–21 | 1.43 | (1.24, 1.65) | *** | 1.57 | (1.39, 1.78) | *** | 1.50 | (1.31, 1.70) | *** |
| 22–34 | 1.60 | (1.37, 1.86) | *** | 1.72 | (1.50, 1.96) | *** | 1.65 | (1.43, 1.89) | *** |
| ≥35 | 1.49 | (1.28, 1.74) | *** | 1.59 | (1.40, 1.82) | *** | 1.55 | (1.35, 1.78) | *** |
| Total BC screening centers | |||||||||
| 0–1 | 1 | 1 | 1 | ||||||
| 2–3 | 1.07 | (0.90, 1.26) | 1.01 | (0.88, 1.17) | 1.05 | (0.90, 1.22) | |||
| 4–7 | 1.18 | (0.99, 1.41) | 1.08 | (0.93, 1.26) | 1.09 | (0.93, 1.27) | |||
| ≥8 | 1.02 | (0.84, 1.24) | 0.93 | (0.78, 1.11) | 0.98 | (0.82, 1.18) | |||
| SEER region | |||||||||
| North east | 0.89 | (0.76, 1.04) | 0.76 | (0.66, 0.87) | *** | 0.75 | (0.65, 0.87) | *** | |
| South | 1.09 | (0.93, 1.28) | 0.96 | (0.83, 1.10) | 1.03 | (0.89, 1.19) | |||
| North central | 0.94 | (0.80, 1.11) | 0.80 | (0.70, 0.93) | ** | 0.76 | (0.65, 0.88) | *** | |
| West | 1 | 1 | 1 | ||||||
The regressions also include intercept terms and parameter estimates for other variable controlled are not presented. “Distant stage at breast cancer diagnosis” is the reference group for the dependent variable
PCP primary care physicians, BC breast cancer; LE less than or equal to; GT greater than; LT less than; GE greater than or equal to Asterisks represent statistically significant group differences compared with the reference group.
***
P < 0.001;
**
001 ≤ P < 0.01;
*
0.01 ≤ P < 0.05
Bold values represent the reference group within each variable